ASCO GU 2026: Updates in metastatic prostate cancer
Dr Park presents at ASCO 2016, the results of a National Cancer Institute (NCI) funded phase III trial performed by the Children’s Oncology Group which found that adding a second autologous stem-cell transplant (ASCT, a transplant that uses the patient’s own stem cells) to standard therapy improves outcomes for these patients.
Read the news story and watch the video interview for more.
ASCO GU 2026: Updates in metastatic prostate cancer
KRdc as induction therapy shows improved OS for NDMM patients
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Advancements in paediatric Acute lymphoblastic leukemia management
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
GIST tumours and soft tissue sarcomas